CHK1 (SRA737)/PARPi combination methods of inhibiting tumor growth
AssigneeSierra Oncology, Inc.
InventorsChristian Andrew Hassig, Bryan William Strouse, Ryan James Hansen, Kenna Lynn Anderes
Life of this patent
Estimating the term…
Abstract
Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models for tumors. Also provided for are methods for treating disorders or diseases mediated or affected by Chk1 and/or PARP activity.
Claims21
A method of inhibiting a tumor growth in a subject in need thereof, comprising administering to the subject a first effective amount of SRA737 comprising a structure of
- and a second effective amount of a poly ADP ribose polymerase (PARP) inhibitor (PARPi), wherein the subject has a cancer that is resistant to PARPi therapy, wherein the cancer is breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer, and wherein the PARPi is talazoparib, niraparib, or rucaparib.
A method of reducing cellular proliferation of a cell, comprising contacting the cell with a first effective amount of SRA737 comprising a structure of
- and a second effective amount of a poly ADP ribose polymerase inhibitor (PARPi), wherein the cell is a cancer tumor cell that is resistant to PARPi therapy, wherein the cancer cell is a breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer cell, and wherein the PARPi is talazoparib, niraparib, or rucaparib.
Dependencies are inferred from the claim text.